Released Aug 1, 2022, before the open
10-Q filed Aug 1, 2022, 32 days after period end · 0001171843-22-005187
Q2 2022 · 10-Q
Revenue—
Net Income-$8.49M-$8.49M N/M vs Q2 2021N/M vs Q1 2022
EPS, diluted—
Operating Income-$8,987,000N/M
Operating Cash Flowderived-$4,600,000N/M
Free Cash Flowderived-$4,537,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 |
|---|---|---|---|---|
| Net Income | -$8.49M | -$55.80M | -$5.56M | -$8.81M |
| EPS Diluted | — | -$1.07 | -$0.41 | -$1.33 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR